Agoracom Blog

The Roundup – @Novamind_Inc $ $NVMDF $ $MMED $ $ $CMPS $

Posted by AGORACOM-JC at 9:34 AM on Saturday, August 21st, 2021

A weekly summary of Novamind news and media

August 17, 2021

Psychedelics, Psychosis, & the Abuse Potential of Ketamine

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison talk about the relationship between psychedelics and psychosis and discuss the abuse potential of ketamine.

Learn more, subscribe and catch up on previous episodes you may have missed at 

View all media

Psychedelics are getting closer to approval, but the market may not be ready

Amirah Al Idrus explores the regulatory issues facing psychedelics, the setting in which they’re administered and how traditional business models may need to evolve in the process. At Novamind, we’re building the infrastructure to expand access to psychedelics in anticipation of their FDA approval. We’ve developed and are developing psychedelic therapy protocols to target difficult-to-treat mental health conditions that are underserved by the current standard of care. You can learn more about those treatment protocols here.

We Just Got Closer to Understanding Why Ketamine Is Such a Powerful Antidepressant

We know ketamine’s power to treat depression. “Within hours, a single dose of the psychedelic substance has been shown to curb suicidal intent, and recent clinical trials suggest these effects work on two thirds of patients, lasting for up to several weeks before fading away.” But recent results are getting us closer to the scientific reason why—ketamine may be responsible for decreasing the release of glutamate in our brains. 

Follow @novamind_inc on Instagram

For further information, email us: 
[email protected]

Subscribe to our weekly newsletter

Tags: , , , ,

Comments are closed.